Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)
Venture and Other News
Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)
Winter Storm Fern Cripples Half the Country This Weekend
CNBC: $100B expected economic loss and damages from storm (Link)
CNBC: Transportation Sec. Duffy says air travel will return to normal by Wednesday (Link)
The Weather Channel: Winter Storm Fern Turns Deadly In Louisiana, Outages For Hundreds Of Thousands Vulnerable To Ice, Snow (Link)
National Public Radio: As the winter storm rages, here’s what to know in your state(Link)
GSK (NYSE:GSK) pays $2.2B to acquire Rapt Therapeutics (NASD:RAPT) and Food Allergy Antibody Ozureprubart GSK is acquiring Rapt Therapeutics for $58 per share, gaining global (ex‑China) rights to ozureprubart, an extended‑half‑life anti‑IgE antibody being studied as a 12‑weekly prophylactic treatment for food allergies. Unlike currently approved IgE inhibitors that require injections every 2–4 weeks, ozureprubart aims to offer sustained protection with less frequent dosing while targeting the same validated pathway as Xolair. The deal follows Rapt’s strategic pivot away from its CCR4 inhibitor program after clinical setbacks and positions ozureprubart for phase 2 readout in 2027 and a planned phase 3 program, backed by GSK’s global development and commercialization infrastructure. (Link)
BioCryst (NASD: BCRX) acquires Astria Therapeutics (NASD:ATXS) in $700M deal to Build Comprehensive Hereditary Angioedema Treatment Platform The transaction adds Navenibart, a long-acting plasma kallikrein inhibitor in Phase 3, which is being developed as a prophylactic HAE treatment with every‑three or every‑six month dosing to improve patient convenience and attack control. BioCryst now pairs its existing oral therapy ORLADEYO with a potential injectable option to give clinicians more flexibility in tailoring care. The deal also brings STAR0310, an early atopic dermatitis program for which strategic options will be explored, and augments BioCryst’s leadership with Astria’s former CEO joining the board and a senior development leader taking charge of technical operations. (Link)
Georgia ProtonCare Center, Inc. Files Chapter 11 to Facilitate Competitive Sale Process and Enters Into Asset Purchase Agreement With Emory Healthcare Georgia ProtonCare Center (GPCC), owner of Georgia’s only proton therapy cancer treatment facility in Midtown Atlanta, has filed for Chapter 11 bankruptcy to facilitate a court-supervised sale process and ensure uninterrupted patient care. The company has signed an asset purchase agreement with Emory Healthcare (via Emory University Hospital Midtown) as the stalking horse bidder to acquire substantially all assets, with Emory clinicians already providing daily treatment at the center. GPCC aims to complete the competitive sale by Q2 2026, prioritizing seamless continuation of precision proton therapy services for cancer patients while operations continue as usual under court-approved funding. (Link)
KidsChoice Announces Majority Investment from Aquitaine Capital to Support Growth and Clinical Excellence KidsChoice, an Oklahoma-based provider of clinic-centered autism and pediatric therapy services including ABA, speech, and occupational therapy, has secured a majority investment from women-owned private equity firm Aquitaine Capital to fuel expansion, enhance clinical excellence, and strengthen infrastructure. The partnership supports thoughtful growth through new clinic openings, strategic M&A, and complementary offerings while prioritizing individualized, outcomes-driven care for children and families. (Link)
Community Health Systems Sells Crestwood Medical Center to Huntsville Hospital Health System in $450M Deal The transaction will transfer Crestwood Medical Center, a 180‑bed acute care hospital in Huntsville, Alabama, along with a freestanding emergency department in Harvest and multiple clinics and outpatient assets, to a regional nonprofit operator. Crestwood’s roughly 1,000 employees will continue normal operations with no planned changes to services or medical staff privileges during the transition. Huntsville Hospital Health System, already a major 14‑hospital network across northern Alabama and southern Tennessee, views the deal as a way to better coordinate local care as Huntsville’s population rapidly grows, while the seller continues its strategy of divesting assets to strengthen its financial position. (Link)
BioStem Technologies (OTC: BSEM) and BioTissue sign Up to $40M Surgical and Wound Care Asset DealThe transaction adds BioTissue’s Neox and Clarix placental- and umbilical‑tissue allograft product lines, along with a national direct and independent sales force and key group purchasing organization contracts, giving BioStem an immediate presence in hospital inpatient and outpatient settings. The acquired surgical and wound care assets, which generated about $29 million in 2025 sales, broaden BioStem’s chronic and acute wound care portfolio and create entry into high‑value segments such as burns and soft‑tissue repair. Deal terms include an upfront $15 million cash payment plus up to $25 million in potential regulatory and commercial milestone payments. (Link)
Harmony Healthcare IT acquires Blue Elm, via its financial sponsor Novacap to build Comprehensive MEDITECH Data Lifecycle Platform Harmony Healthcare IT has acquired Blue Elm to offer MEDITECH hospitals a single, end-to-end partner for data extraction, conversion, migration, archiving, optimization, and real-time access across all MEDITECH versions. The combined capabilities help hospitals retire costly legacy systems, strengthen data integrity, and improve accessibility as they upgrade or transition EHR platforms. By unifying services under one organization and relying on U.S.-based resources instead of offshore outsourcing, the company aims to shorten complex project timelines, enhance security and quality, and better support hospitals under pressure to improve care quality while reducing operating costs. (Link)
PhaseWell Research acquires Bio Behavioral Health Partner, via its financial sponsor Shore Capital Partners to expand Community-Based Neuropsychiatric Clinical Trials The acquisition will strengthen PhaseWell’s national network of community clinical research sites focused on neurologic and psychiatric disorders. The collaboration aims to broaden patient access to neuropsychiatric trials by leveraging BBH’s experience in community-based studies and PhaseWell’s nationwide platform and infrastructure. Together, the organizations plan to support sponsors with reliable patient enrolment, strong operational execution, and high-quality data while advancing next-generation CNS therapeutics across complex therapeutic areas, including oncology, cardiovascular/metabolic conditions, and dermatology. (Link)
Pair Team acquires Town Square to Advance AI-Enabled Community Care for Medicare and Medicaid Beneficiaries The acquisition combines an AI-driven medical group with a social care coordination platform to better integrate clinical, behavioral, and social services for underserved populations. Technology will orchestrate complex, cross-setting care tasks so human teams can concentrate on clinical decisions, hands-on support, and relationships with patients and local organizations. Town Square’s founder will lead network expansion and community partnerships within the new structure, which emphasizes responsible AI, robust outcomes measurement, and investment in community-based infrastructure to extend whole-person care to people historically excluded from the healthcare system. (Link)
Aspen Surgical expands Infection Prevention Portfolio with acquisition of Ruhof Healthcare, via its financial sponsors Linden and Audax Private Equity The buyer is adding enzymatic detergents, cleaning verification tools, and automated and manual instrument and endoscope reprocessing solutions to deepen its presence in operating rooms, sterile processing, and endoscopy settings. Ruhof’s portfolio, including Endozime detergents, ScopeValet single-use consumables, CleanRead ATP contamination monitoring, and instrument refurbishment services, will bolster the SPD360 Performance Solutions platform and complement existing brands such as Symmetry, Bookwalter, and Precept. The transaction covers all Ruhof operations, brands, and product lines, with integration set to begin immediately and no near-term disruption expected for customers, suppliers, or employees. (Link)
TridentCare acquires DispatchHealth Imaging Unit to Grow National Portable Diagnostics Network The acquisition adds a multistate mobile X‑ray and ultrasound operation that serves patients at home, in post‑acute facilities, and in correctional settings, expanding TridentCare’s reach and capacity. By integrating these imaging teams and customers into its national infrastructure, TridentCare aims to speed response times, improve scheduling flexibility, and deliver more consistent service quality for clinicians and patients. DispatchHealth will continue focusing on providing complex care in the home and will coordinate imaging through technology and partnerships so patients and providers experience seamless, integrated services. (Link)
Morris & Dickson Completes Transaction to Acquire Prodigy Health Morris & Dickson (M&D), the nation’s largest independent wholesale and specialty pharmaceutical distributor, has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company focused on plasma-derived therapies. The transaction expands M&D’s specialty portfolio, broadens access to plasma therapies for hospitals, clinics, infusion centers, and alternative care sites nationwide, and strengthens its independent platform for manufacturers through a compliance-first approach. (Link)
Main Post Partners and HomeWell Leadership acquire HomeWell Franchising to Accelerate Senior In‑Home Care Growth The deal pairs a national non‑medical home care franchisor with a private equity firm experienced in franchising and consumer service brands, aiming to fuel the next phase of expansion. The partners emphasize a “partnership, not ownership” philosophy, focusing on close collaboration with franchisees and caregivers to scale services while preserving mission and culture. Building on several years of rapid revenue growth and record franchise development, the company plans to invest in tools, resources, and support that help local agencies grow and better serve seniors and homebound individuals in their communities. (Link)
Venture and Other News
Zarminali Paediatrics raises $110M in Series A funding led by Healthier Capital, with participation from General Catalyst, K2 HealthVentures, and Boston Children’s Hospital to expand integrated paediatric care footprint The company will use the new capital to scale its proprietary tech platform, enter additional states and open de novo clinics while continuing to acquire established paediatric groups. Its model centers on a single branded multispecialty practice that co-locates clinics with urgent care, directly employing both paediatricians and specialists to coordinate care across the full continuum outside the hospital. Since launching in 2024, Zarminali has rapidly expanded to 28 clinics in eight states and plans at least 15 new sites in 2026, while laying groundwork for future value-based arrangements and building analytics to track clinician performance and patient outcomes. (Link)
Mendra launches with $82M Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC to advance AI-driven rare disease therapeutics Mendra will use the oversubscribed financing to acquire and develop an initial portfolio of high-potential rare disease assets while applying AI to speed patient identification, trial enrollment and global market access. The company is built to modernize how rare disease medicines are developed and commercialized so they reach underserved patients more efficiently worldwide. A veteran leadership team with deep experience in rare disease drug development, global commercialization and AI—drawn from organizations such as BioMarin, Modis Therapeutics, Escient Pharmaceuticals, Palantir and Bayer—will guide strategy across asset selection, clinical execution and business development. (Link)
AnswersNow raises $40M in Series B funding led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to Scale AI-Enabled Virtual Autism Therapy The company will use the new capital to expand its platform, double clinical headcount, add senior leaders and launch new service lines to meet surging demand for autism support. Its AI-driven model pairs families across the U.S. with Master’s- and PhD-level BCBAs for targeted, parent-mediated virtual ABA, cutting weekly therapy time from 30+ hours to about 4–5 while sustaining strong clinical gains. Outcomes data show high family-reported improvements, substantial cost savings for payors and a consistently strong satisfaction score, with forthcoming research in 2026 intended to further validate clinical and economic impact. (Link)
BrightInsight secures $13M investment from Eclipse, General Catalyst, Insight Partners, Mayo Clinic and New Leaf Venture Partners to scale its AI-enabled medication adherence platform The company will deploy the capital to expand its AI-enabled persistence and adherence solutions, including a co-developed Patient App used across multiple diseases and therapies worldwide. By leveraging real-world data and advanced analytics, the platform targets chronically low adherence rates, aiming to predict churn and trigger personalized interventions that keep patients on therapy. BrightInsight reports strong patient engagement and one-year retention across programs and plans to deepen its product roadmap, broaden disease and biopharma partnerships, and add support for caregivers and nurse educators to ease pressure on health systems. (Link)
McKinsey & Co Released their Annual Healthcare Outlook Report. To remain competitive in 2026 and beyond, healthcare leaders must improve performance, embrace technology and rethink traditional care models(Link)
IPO Watchlist
Once Upon a Farm — Organic children’s food company co-founded by Jennifer Garner, is targeting a valuation of up to $764.4 million in its upcoming U.S. IPO on the NYSE under the ticker OFRM. (Link)
Kallyope — New York City-based biotechnology company specializing in novel therapeutics targeting the gut-brain axis and neural circuits.
Kardium — Vancouver area based medical device company focused on cardiac electrophysiology solutions; develops advanced catheter-based systems for the diagnosis and minimally invasive treatment of atrial fibrillation.
Tenpoint Therapeutics — London, UK-headquartered (with U.S. operations in Seattle and Irvine) ophthalmic biotechnology company dedicated to age-related vision restoration therapies.
Vensure Employer Solutions — Chandler, AZ -based professional employer organization (PEO) and provider of human capital management (HCM) technology serving the healthcare and broader employer ecosystem.
